Treating HFD-induced obese mice and ob/ob mice with liver-directed adeno-associated virus (AAV)-BMP7 vectors increases circulating BMP7 levels, induces the browning of WAT, activates BAT, alleviates hepatic steatosis, and normalizes body weight and insulin resistance (Casana et al., 2022), highlights the potential of AAV-BMP7-mediated gene therapy for the treatment of MASLD/MASH. Here, BMP7 is linked to fatty liver disease.